In 70 high-CMV-risk kidney transplant recipients, maribavir 400 mg twice daily vs valganciclovir 900 mg daily prophylaxis showed no significant difference in clinically significant leukopenia (22.9% vs 5.7%, P=.084); valganciclovir had more days with low white cell counts.
RCTn = 70
Taber et al. Single-center, open-label, randomized controlled trial comparing the tolerability of maribavir 400 mg twice daily versus standard-dose valganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients